Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
ScripArcturus Therapeutics and licensing partner CSL have got approval in the EU for Kostaive, a self-amplifying mRNA (sa-mRNA) vaccine that the firms hope will become a major product in the COVID-19 space
Pink SheetA self-amplifying mRNA vaccine for COVID-19, Arcturus Therapeutics’ Kostaive (ARCT-154), has been the subject of extensive disparaging and scientifically inaccurate comments online in its first market